---
layout: default
title: Amikacin Sulfate
parent: 僅模型預測 (L5)
nav_order: 44
evidence_level: L5
indication_count: 0
---

# Amikacin Sulfate
{: .fs-9 }

證據等級: **L5** | 預測適應症: **0** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Amikacin Sulfate: Repurposing Evaluation — Insufficient Data to Proceed

## One-Sentence Summary

Amikacin sulfate is an aminoglycoside antibiotic with established activity against multidrug-resistant Gram-negative organisms and mycobacteria.
The current Evidence Pack contains **no TxGNN-predicted indications**, and regulatory, safety, and mechanism data are all unavailable.
A repurposing evaluation cannot be completed until the data gaps identified below are resolved.

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | Not available in current data |
| Predicted New Indication | None |
| TxGNN Prediction Score | N/A |
| Evidence Level | L5 — no predictions or supporting studies available |
| Market Status (Taiwan) | Not marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |

---

## Why is This Prediction Reasonable?

No TxGNN-predicted indications are present in this Evidence Pack, so a mechanism-based repurposing rationale cannot be constructed. This section will be completed once a target indication is identified.

For reference: amikacin sulfate is a semi-synthetic aminoglycoside that inhibits bacterial protein synthesis by irreversibly binding the 30S ribosomal subunit, causing mRNA misreading and bactericidal activity. It retains coverage against many organisms resistant to other aminoglycosides due to its unique side-chain that prevents enzymatic inactivation. This mechanism is antibacterial in nature and would require careful examination of any non-infectious predicted indication to establish plausibility.

---

## Safety Considerations

Please refer to the SmPC for safety information.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The Evidence Pack is missing all three elements required to begin a repurposing evaluation — predicted indications, mechanism of action, and regulatory safety data — making it impossible to assess candidate viability at this stage.

**To proceed, the following is needed:**

- **Run TxGNN prediction pipeline** for amikacin sulfate to generate candidate disease indications; without at least one prediction, no evaluation workflow can begin
- **Parse the DrugBank result** — the query log confirms a successful hit (2026-03-26, result\_count: 1), but the DrugBank ID was not recorded and MOA data was not extracted; this should be resolved immediately as it is a High-severity gap
- **Retrieve the regulatory label** (SmPC or equivalent package insert) to populate safety warnings, contraindications, and dosing context; this is currently a Blocking gap
- **Confirm market authorization scope** — verify whether amikacin sulfate holds approvals in any jurisdiction relevant to the repurposing target (EU, US, Japan, etc.)
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

